The Effects of Cannabis on Dystonia and Spasticity on Pediatric Patients
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
A clinical trial is planned to study the effects of cannabis on dystonia and spasticity in
children with neurological diseases. The clinical trial will include 40 children divided into
two groups: children with spasticity and dystonia due to cerebral palsy, and children with
spasticity and dystonia due to genetic neurodegenerative diseases. Each group will be
randomly divided into two arms and will receive Avidekel cannabis oil 6-to-1 ratio of CBD to
THC or enriched Avidekel cannabis oil 20-to-1 ratio of CBD to THC. During the study, various
variables will be collected including: medication intake, spasticity, dystonia score, pain
scale, restlessness scale, quality of life measures, safety tests, side effects, and an
addiction test. The investigators hypothesize that cannabis consumption will reduce dystonia
and spasticity in children with motor disability related to genetic neurodegenerative
diseases and cerebral palsy and as a result improve motor function, non-motor functions and
quality of life.